177Lu-PSMA靶向治疗转移性去势抵抗性前列腺癌的研究进展

Progress in radioligand therapy with 177Lu-PSMA for the treatment of metastatic castrationresistant prostate cancer

前列腺癌是男性最常见的恶性肿瘤之一,尽管现有的治疗方法对多数前列腺癌患者可取得较好疗效,但对转移性去势抵抗性前列腺癌的治疗仍然极具挑战性,迫切需要发展更有效的治疗方法。目前,177Lu标记的前列腺特异性膜抗原靶向治疗是最有希望的新疗法之一,有望成为前列腺癌的标准治疗方案之一,该疗法安全、有效,可延长患者的总体生存期。

Prostate cancer is one of the most common malignancies worldwide. Many advances have been made over the past years, but the treatment of metastatic prostate cancer remains challenging. In many cases, existing therapies have become ineffective for controlling tumor progression. Thus, new approaches are urgently needed. Radioligand therapy with 177Lu-Prostate specific membrane antigen (PSMA) is an innovative and effective therapy for patients with castrationresistant metastatic prostate cancer. PSMA is expected to be a standard regimen for prostate cancer as it is well tolerated by patients and has high potential for improving overall survival.